ArticleInternational journal of radiation oncology, biology, physics2021
Localized Delivery of Cisplatin to Cervical Cancer Improves Its Therapeutic Efficacy and Minimizes Its Side Effect Profile.
Article in International journal of radiation oncology, biology, physics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Comparing the effectiveness of various cumulative doses of cisplatin in treating locally advanced nasopharyngeal cancer during the period of intensity-modulated radiotherapy: a meta-analysis.Frontiers in medicine · 2026Pooled it
- Astragalus polysaccharides combined with radiochemotherapy for cervical cancer: a systematic review and meta-analysis of randomized controlled studies.Frontiers in pharmacology · 2025Pooled it
- Aloe vera extract disrupts mitochondrial bioenergetics and suppresses HeLa cervical cancer cell proliferation: Transcriptomic and metabolic insights into cisplatin co-treatment.Journal of bioenergetics and biomembranes · 2026Article
- Synergistic Effect of Digoxin and Cisplatin on Redox Imbalance in HeLa Cells.Cell biochemistry and function · 2026Article
- Review
- Comparative effects of intranasal and intraperitoneal resveratrol on the eye-brain axis in a cisplatin-induced neurotoxic rat model.Scientific reports · 2026Article
- Epithelial-mesenchymal transition and its role in drug resistance of cervical cancer.Molecular biology reports · 2026Review
- MCPyV small T antigen enhances HPV16 oncogene expression, promotes Ca Ski cell proliferation, and reduces 5-fluorouracil-induced apoptosis in cervical cancer cells.Infectious medicine · 2025Article
- Emerging nanotherapeutics for HPV-associated cancers: current advances, challenges, and future directions.Discover oncology · 2025Review
- Retinoic Acid-Induced Transglutaminase 2 Expression Reduces Sensitivity to Cisplatin in the Hormone-Positive MCF-7 Breast Cancer Cell Model.International journal of molecular sciences · 2025Article
- Role of Fascin-1 in cervical cancer metastasis via Wnt/β-catenin pathway activation.Biomolecules & biomedicine · 2025Article
- Dual Topoisomerase Inhibitor Is Highly Potent and Improves Antitumor Response to Radiotherapy in Cervical Carcinoma.International journal of molecular sciences · 2025Article
- Comparison of two platinum-containing chemotherapy regimens in the treatment of advanced cervical cancer with concurrent chemoradiotherapy.Annals of medicine · 2024Article
- hUCMSC-derived extracellular vesicles relieve cisplatin-induced granulosa cell apoptosis in mice by transferring anti-apoptotic miRNAs.Journal of biomedical research · 2024Article
- Implantation of In Situ Gelling Systems for the Delivery of Chemotherapeutic Agents.Gels (Basel, Switzerland) · 2024Review
- Molecular Actions ofAnti-cancer agents in medicinal chemistry · 2024Article
- MicroRNA-875-5p inhibits the growth and metastasis of cervical cancer cells by promoting autophagy and apoptosis and inhibiting the epithelial-mesenchymal transition.Frontiers in oncology · 2024Article
- Anti-tumor Effects of Cisplatin Synergist in Combined Treatment withAdvanced pharmaceutical bulletin · 2023Article
- Anticancer perspective of 6-shogaol: anticancer properties, mechanism of action, synergism and delivery system.Chinese medicine · 2023Review
- Gold-Enhanced Brachytherapy by a Nanoparticle-Releasing Hydrogel and 3D-Printed Subcutaneous Radioactive Implant Approach.Advanced healthcare materials · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
purposeCervical cancer represents the fourth most frequent malignancy in the world among women, and mortality has remained stable for the past 4 decades. Intravenous cisplatin with concurrent radiation therapy is the standard-of-care for patients with local and regional cervical cancer. However, cisplatin induces serious dose-limiting systemic toxicities and recurrence frequently occurs. In this study, we aimed to develop an intracervical drug delivery system that allows cisplatin release directly into the tumor and minimize systemic side effects. METHODS AND MATERIALS: Twenty patient biopsies and 5 cell lines treated with cisplatin were analyzed for platinum content using inductively coupled plasma mass spectrometry. Polymeric implants loaded with cisplatin were developed and evaluated for degradation and drug release. The effect of local or systemic cisplatin delivery on drug biodistribution as well as tumor burden were evaluated in vivo, in combination with radiation therapy.
resultsPlatinum levels in patient biopsies were 6-fold lower than the levels needed for efficacy and radiosensitization in vitro. Cisplatin local delivery implant remarkably improved drug specificity to the tumor and significantly decreased accumulation in the blood, kidney, and other distant normal organs, compared with traditional systemic delivery. The localized treatment further resulted in complete inhibition of tumor growth.
conclusionsThe current standard-of-care systemic administration of cisplatin provides a subtherapeutic dose. We developed a polymeric drug delivery system that delivered high doses of cisplatin directly into the cervical tumor, while lowering drug accumulation and consequent side effects in normal tissues. Moving forward, these data will be used as the basis of a future first-in-human clinical trial to test the efficacy of localized cisplatin as adjuvant or neoadjuvant chemotherapy in local and regional cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.